In summary, these findings facilitate the novel therapeutic strategies of GMI via activating DNAJA3 to promote mitochondrial homeostasis and subsequently to mediate muscle function enhancement, metabolic syndrome amelioration and sarcopenic obesity resistance. The gene discussed is DNAJA3; the disease is Obesity.